A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons.
Authors:
- 28 February 1995
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 92 (5) , 1719-1723
Abstract
The effects of interruption of dopaminergic transmission or sustained blockade of dopamine receptors by neuroleptics on the dopamine D3 receptor in the shell of the nucleus accumbens were investigated in rats. In this brain area the D3 receptor is abundant and may mediate antipsychotic drug effects. The D3 receptor density and mRNA abundance were evaluated with 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin and by quantitative PCR or image analysis of in situ hybridization signals, respectively. Unilateral dopamine neuron degeneration by 6-hydroxydopamine or sections triggered, after a few days, a marked decrease (up to 50%) in D3 receptor binding and mRNA in the nucleus accumbens. In contrast, a 2-week treatment with the neuroleptic haloperidol (20 mg/kg) had no effect on D3 receptor density and mRNA but enhanced D2 receptor density and mRNA level by > 50%. In addition, tolerance to the haloperidol-induced change of neurotensin mRNA mediated by the D2 receptor developed, but there was no tolerance to the opposite change mediated by the D3 receptor. Reserpine, a monoamine-depleting drug with antipsychotic activity, did not modify D3 receptor mRNA. These observations reinforce the idea that the D3 receptor may be an important target for neuroleptics whose antipsychotic actions, but not extrapyramidal motor actions, do not display tolerance. The D3 receptor mRNA level was also decreased by a unilateral injection in dopamine cell body areas of colchicine, a drug blocking the anterograde axonal transport, or by baclofen, a type A gamma-aminobutyric acid receptor agonist reducing dopamine neuron activity, but not by sustained blockade of D1-like and D2-like, neurotensin, or cholecystokinin receptors. We therefore propose that an anterograde factor present in mesolimbic dopaminergic neurons, but distinct from dopamine and known peptide cotransmitters, plays a positive role on transcription of the D3 receptor gene.Keywords
This publication has 41 references indexed in Scilit:
- Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell lineEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- The effect of haloperidol on D2 dopamine receptor subtype mRNA levels in the brainFEBS Letters, 1994
- Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptorEuropean Journal of Pharmacology: Molecular Pharmacology, 1992
- Effects of Dopaminergic Transmission Interruption on the D2 Receptor Isoforms in Various Cerebral TissuesJournal of Neurochemistry, 1992
- Cloning and functional characterization of a cocaine‐sensitive dopamine transporterFEBS Letters, 1991
- Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamineExperimental Neurology, 1991
- D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal NeuronsScience, 1990
- Lack of effect of chronic dopamine receptor blockade on D2 dopamine receptor mRNA levelNeuroscience Letters, 1990
- Evidence for coexistence of dopamine and CCK in meso-limbic neuronesNature, 1980
- Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activityLife Sciences, 1978